PARTICULARS TO APPEAR ON THE OUTER PACKAGE {CARTON}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Pimocard 2.5 mg flavoured tablets

2. STATEMENT OF ACTIVE SUBSTANCES

Each tablet contains:
Pimobendan 2.5 mg

3. PACKAGE SIZE

20 tablets
50 tablets
100 tablets
250 tablets

4. TARGET SPECIES

Dogs.

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Oral use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

Shelf life of divided tablets after first opening the blister: 3 days.

9. SPECIAL STORAGE PRECAUTIONS

Do not store above 30 °C.
Return any divided tablet to the opened blister.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Eurovet Animal Health B.V.

14. MARKETING AUTHORISATION NUMBERS

Vm 16849/5021
Vm 16849/3021

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS {BLISTER}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Pimocard

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Pimobendan 2.5 mg/tablet

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Pimocard 1.25 / 2.5 / 5 / 10 mg flavoured tablets for dogs

2. Composition

Each tablet contains:

Active substances:
Pimobendan 1.25 / 2.5 / 5 / 10 mg

Light brown round tablets, scored on one side and plain on the other side.
The tablets can be divided into 2 (1.25 mg) or 4 (2.5 mg, 5 mg and 10 mg) equal parts.

3. Target species

Dogs.

4. Indications for use

For the treatment of canine congestive heart failure originating from valvular insufficiency (mitral and/or tricuspid regurgitation) or dilated cardiomyopathy.

5. Contraindications

Do not use in cases of hypertrophic cardiomyopathies or diseases in which an improvement in cardiac output cannot be achieved for functional or anatomical reasons (e.g. aortic stenosis).
Since pimobendan is metabolised mainly via the liver, do not use in dogs with severe impairment of liver function. See also ‘Pregnancy and lactation’ under ‘Special warnings’ section.

6. Special warnings

Special precautions for safe use in the target species:
Blood glucose should be tested regularly during treatment in dogs with existing diabetes mellitus.

Monitoring of cardiac function and morphology is recommended in animals treated with pimobendan.
See also the ‘Adverse events’ section.

The tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of animals.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Wash hands after use.
To the physician: accidental ingestion, especially by a child, may lead to the occurrence of tachycardia, orthostatic hypotension, flushing of the face and headaches.
This veterinary medicinal product may cause cardiovascular effects in the event of accidental ingestion.

Pregnancy and lactation:
Laboratory studies in rats and rabbits have not produced any evidence of teratogenic or foetotoxic effects. However, these studies have shown evidence of maternotoxic and embryotoxic effects at high doses, and have also shown that pimobendan is excreted into milk.
The safety of the veterinary medicinal product has not been assessed in pregnant or nursing bitches. Use only according to the benefit-risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:
In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected. The pimobendan-induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and diltiazem and the β-antagonist propranolol.

Overdose:
An overdose may cause vomiting, a positive chronotropic effect, apathy, ataxia, heart murmurs or hypotension. In this situation, the dosage should be reduced and appropriate symptomatic treatment should be initiated.
In prolonged exposure (6 months) of healthy beagle dogs at 3 and 5 times the recommended dose, mitral valve thickening and left ventricular hypertrophy were observed in some dogs. These changes are of pharmacodynamic origin.

7. Adverse events

Dogs:

Rare (1 to 10 animals / 10 000 animals treated):	Increased heart rate[1,2], Increase in mitral valve regurgitation[3] Vomiting[2], Diarrhoea[4] Anorexia[4] (loss of appetite), Lethargy[4] (lack of energy)
Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Mucosa petechiae[5] (small blood spots on mucosa), Haemorrhages (subcutaneous)[5] (bleeding under the skin)

1 Due to a slight positively chronotropic effect.
2These effects are dose-dependent and can be avoided by reducing the dose.
3 Observed during chronic pimobendan treatment in dogs with mitral valve disease.
4 Transient.
5 A relationship with pimobendan has not been clearly established, signs disappear when the treatment is withdrawn.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or its local representative using the contact details at the end of this leaflet, or via your national reporting system:

Website: https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine

e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Oral use.

To ensure a correct dosage, body weight should be determined as accurately as possible.
The tablets should be administered orally at a dose range of 0.2 mg to 0.6 mg pimobendan/kg body weight per day. The preferable daily dose is 0.5 mg pimobendan/kg body weight. The dose should be divided into two administrations (0.25 mg/kg body weight each), one half of the dose in the morning and the other half approximately 12 hours later. Each dose should be given approximately one hour before feeding.
Do not exceed the recommended dosage.

The veterinary medicinal product may be combined with a diuretic treatment such as furosemide.

9. Advice on correct administration

This veterinary medicinal product should be used only in dogs with cardiac insufficiency.
To break a single scored tablet into two halves, place the tablet on an even surface with the scored side up. Hold one half of the tablet and press down on the other half.

To break a double scored tablet into quarters, place the tablet on an even surface with the scored side up and apply pressure on the middle with your thumb.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.
Do not store above 30 °C.
Return any divided tablet to the opened blister and use within 3 days.
Do not use this veterinary medicinal product after the expiry date which is stated on the blister and the carton after Exp. The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 16849/5021
Vm 16849/3021

Pack sizes:
Aluminium-PVC/PE/PVDC blister:
10 tablets per blister: 2, 5, 10 or 25 blisters per carton.

Aluminium-aluminium blister:
1.25 and 2.5 mg tablet: 10 tablets per blister: 2, 5, 10 or 25 blisters per carton.
5 and 10 mg tablet: 5 tablets per blister: 4, 10, 20 or 50 blisters per carton.

Not all pack sizes may be marketed.

15. PID link (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder and manufacturer responsible for batch release:
Eurovet Animal Health B.V.
Handelsweg 25
5531 AE Bladel
The Netherlands

Manufacturer responsible for batch release:
Eurovet Animal Health B.V.
Handelsweg 25
5531 AE Bladel
The Netherlands

Genera d.d.
Svetonedeljska cesta 2, Kalinovica
10436 Rakov Potok
Croatia

Dales Pharmaceuticals Limited
Snaygill Industrial Estate
Keighley Road
Skipton
North Yorkshire
BD23 2RW
United Kingdom

Local representatives and contact details to report suspected adverse events:
Dechra Veterinary Products Limited
Sansaw Business Park
Hadnall
Shrewsbury
Shropshire
SY4 4AS
United Kingdom
Tel: +44 (0) 1939 211200

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

17. Other information

POM-V

When used in cases of symptomatic valvular insufficiency in conjunction with furosemide, the veterinary medicinal product has been shown to improve the quality of life and extend life expectancy in treated dogs.

When used in a limited number of cases of symptomatic dilated cardiomyopathy in conjunction with furosemide, enalapril and digoxin, the veterinary medicinal product has been shown to improve the quality of life and to extend life expectancy in treated dogs.

Approved 23 June 2026
Gavin Hall